John Parkinson

Vaxart enrolled its first participants for its dose-ranging and boosting regimen studies.

The Democratic Republic of the Congo (DRC) reached 42 days without a new case. Guinea, however, has not officially declared its outbreak over yet.

Investigators report the vaccine demonstrated it was safe, well-tolerated, and immunogenic in all age groups.

The companies are seeking approval for anyone aged 16 and above.

Company plans to initiate a rolling submission for US Food and Drug Administration (FDA) Biologics License Application (BLA) this month for the vaccine.

Moderna reports data demonstrating a single 50 µg shot of its mRNA-1273 or mRNA-1273.351 booster shot increased neutralizing titers against SARS-CoV-2, as well as the South African and Brazilian variants.

Amongst HIV negative participants, the vaccine demonstrated a 51% efficaciousness against B.1.351.

The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.

A report said the vaccine may receive a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the 12-15 year old population as early as next week.

The Connecticut, New York, and New Jersey governors announced plans to return to full capacity again.

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

Two cases in the United States showed reinfection after administration of the m-RNA vaccines may complicate protection against new variants, but lend support to a potential need for a booster.

The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.

The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.

Study finds a 10% reinfection rate amongst a mostly 18-20 year old United States Marine population in a closed setting.

Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.

Social identity plays an important role in how antimicrobial stewards see their roles and influences how they communicated with prescribers.

In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.

A recent study looked at the racial disparities amongst people living with HIV and COVID-19 positivity rates.

The company asked the Food and Drug Administration (FDA) to amend their Emergency Use Authorization (EUA) to include 12-15 year olds.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency is making this recommendation for people in this age group after rare blot clots occurred after administration of the AstraZeneca vaccine.

2020 forced clinicians and people with HIV (PWH) to adapt to the COVID-19 pandemic. While initially it had an immediate impact on patient care, new solutions and strategies were created to ensure health care was delivered to those who needed it.

Biopharmaceutical company, NeuroRx, reported positive data from its phase 2/3 trial for its therapy, aviptadil acetate (Zyesami), in patients with severe COVID-19.

A manufacturing plant that was set to produce the Janssen (Johnson & Johnson) vaccine mixed up the ingredients of 2 vaccines.

The joint World Health Organization (WHO)-China Report looked at various scenarios and its theory of an animal to animal to human transmission.

The country’s federal health agency decided upon this action based on the small number of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) incidents in Europe, which are being investigated.

The Moderna and Pfizer-BioNTech vaccines are highly effective and transmission is unlikely.

The companies announced they are expanding their study in children ages 6 months to 11 years old.

The president updated his goal during his press conference this afternoon.